<sup>90</sup>Y-DOTATOC Dosimetry–Based Personalized Peptide Receptor Radionuclide TherapyYusuf Menda, M. Sue O’Dorisio, Sarah L. Mott et al.|Journal of Nuclear Medicine|2018Cited by 51
Enhancing the Efficacy of Melanocortin 1 Receptor-Targeted Radiotherapy by Pharmacologically Upregulating the Receptor in Metastatic MelanomaMengshi Li, Michael K. Schultz, Dijie Liu et al.|Molecular Pharmaceutics|2019Cited by 32
The role of cellular redox imbalance, ER-stress, and autophagy in adaptation of metastatic melanoma to MAPK pathway inhibitionSomya Kapoor, Ling Yang, Andrean Llewela Simons‐Burnett et al.|Unknown|2018Cited by 0